Guggenheim has raised its price target for Verve Therapeutics (VERV, Financial) from $18 to $24, maintaining a Buy rating on the company's shares. This revision follows the promising results from Verve's Heart-2 Phase 1b trial for VERVE-102, which the firm described as a "strikingly clean win."
The positive outcome of the trial has led Guggenheim to increase its probability of success for VERVE-102, raising their expectation from 60% to 75%. The encouraging data from this trial appears to strengthen the company’s potential in the therapeutic field, prompting the firm's optimistic outlook on the stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Verve Therapeutics Inc (VERV, Financial) is $26.83 with a high estimate of $39.00 and a low estimate of $15.00. The average target implies an upside of 551.29% from the current price of $4.12. More detailed estimate data can be found on the Verve Therapeutics Inc (VERV) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Verve Therapeutics Inc's (VERV, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
